CPC A61K 31/713 (2013.01) [A61K 47/545 (2017.08); A61K 47/6929 (2017.08); A61K 47/6949 (2017.08); A61P 19/02 (2018.01); C12N 15/1136 (2013.01); C12N 2310/141 (2013.01); C12N 2320/31 (2013.01)] | 2 Claims |
1. A method of treating rheumatoid arthritis comprising the systemic administration of an effective amount of a rosette nanopiece and a nucleic acid, wherein said nanopiece comprises a compound of Formula I or Formula II,
or a salt thereof,
wherein,
X is CH or N;
R2 is hydrogen or a linker group;
Y is absent when R2 is hydrogen or is an amino acid or polypeptide;
R1 is hydrogen or aliphatic,
wherein the amino acid side chain is selected from:
wherein, the compounds of Formula (I), Formula (II), or a salt thereof, or a combination of Formula (I) and Formula (II) self-assemble to form a nanotube, and
wherein the nucleic acid comprises an siRNA selected from the group consisting of TNF-α siRNA, a sequence comprising AAG CCT GTA GCC CAC GTC GTA (SEQ ID NO: 229), a sequence comprising GGC ACC ACT AGT TGG TTG TCT TTG (SEQ ID NO: 230), an anti-miR-181a comprising SEQ ID NO: 228, and an anti-miR-181a comprising SEQ ID NO: 229.
|